Reveromycin A

Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of epidermal growth factor (EGF). It is a G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Reveromycin A displays antiproliferative behavior against human cell lines KB and K562 as well as potent antifungal activity. More recently it has been shown to inducing apoptosis in osteoclasts thus inhibiting bone resorption.\n\nPurity: >99% by HPLC\n\nSolubility: Soluble in ethyl acetate, ethanol, methanol, DMF or DMSO. Avoid acidic conditions.\n\nRelated to: Reveromycin B, Reveromycin C, Reveromycin D

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

R1988

Size

250ug

Purity

>99% by HPLC\n

References

1. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in \nosteoclasts. Woo J.T. et al. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4729. \n2. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an \nantiosteoclastic activity. Muguruma H. et al. Clin. Cancer Res. 2005, 11, 8822. \n3. Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific \ninhibitor Reveromycin A. Miyamoto Y. et al. J. Biol. Chem. 2002, 277, 28810. \n4. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. Takahashi H. et al. J. \nAntibiot. 1992, 45, 1414.